Ambitious plans but no cash for UK biotechnology
This article was originally published in Clinica
No new funds will be made available to fund the UK government's cross-departmental "Biotechnology Crusade". The President of the Board of Trade, Ian Lang, launched the crusade, a cross-departmental drive to boost Britain's biotech industry, at the Institute of Directors, in London, last week. He said priorities include intellectual property protection and a competitive regulatory climate. The Ministers of Health, Food, Science and Technology, Agriculture, Forestry and Environment, the Scottish Office and Small Businesses all attended the launch but none had new money to support their plans.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.